Baird analyst Eric Coldwell lowered the firm’s price target on Quest Diagnostics to $140 from $151 and keeps a Neutral rating on the shares. The firm said they provided a solid update, showed progress was evident, and the core is strong. However, PAMA, COVID comps, and investment dilution remain front and center of debate.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on DGX:
- Quest Diagnostics price target lowered to $145 from $155 at Truist
- Quest Diagnostics announces collaboration with Diadem SpA
- Quest Diagnostics price target lowered to $130 from $142 at Citi
- Quest Diagnostics narrows FY23 adjusted EPS view to $8.65-$8.75 from $8.50-$8.90
- Quest Diagnostics Reports Third Quarter 2023 Financial Results; Updates Guidance for Full Year 2023